Zhejiang Starry Pharm Co Ltd (603520) — Capital Reinvestment Ratio
Zhejiang Starry Pharm Co Ltd (603520) has a Capital Reinvestment Ratio of 2.67x as of September 2025, meaning it reinvests 3% of its operating cash flow (CN¥9.76 Million) in capital expenditures (CN¥26.10 Million). See Zhejiang Starry Pharm Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhejiang Starry Pharm Co Ltd Capital Reinvestment Ratio (2012–2025)
This chart tracks Zhejiang Starry Pharm Co Ltd's Capital Reinvestment Ratio across 13 annual periods. Check total reinvestment intensity of Zhejiang Starry Pharm Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Zhejiang Starry Pharm Co Ltd (2012–2025)
Year-by-year Capital Reinvestment Ratio for Zhejiang Starry Pharm Co Ltd from 2012 to 2025. For live market cap and broader valuation context, see how much is Zhejiang Starry Pharm Co Ltd worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 73.42x | CN¥3.67 Million | CN¥269.20 Million | ▲ +2855.8% |
| 2024 | 2.48x | CN¥193.50 Million | CN¥480.62 Million | ▼ -57.0% |
| 2023 | 5.77x | CN¥46.13 Million | CN¥266.22 Million | ▲ +866.5% |
| 2021 | 0.60x | CN¥508.84 Million | CN¥303.88 Million | ▼ -32.0% |
| 2020 | 0.88x | CN¥174.48 Million | CN¥153.17 Million | ▲ +62.5% |
| 2019 | 0.54x | CN¥246.77 Million | CN¥133.28 Million | ▼ -36.2% |
| 2018 | 0.85x | CN¥191.84 Million | CN¥162.40 Million | ▼ -83.1% |
| 2017 | 5.01x | CN¥18.10 Million | CN¥90.62 Million | ▼ -79.6% |
| 2016 | 24.55x | CN¥7.68 Million | CN¥188.51 Million | ▲ +851.9% |
| 2015 | 2.58x | CN¥94.88 Million | CN¥244.66 Million | ▲ +79.6% |
| 2014 | 1.44x | CN¥144.00 Million | CN¥206.76 Million | ▼ -42.9% |
| 2013 | 2.51x | CN¥74.99 Million | CN¥188.42 Million | ▲ +87.8% |
| 2012 | 1.34x | CN¥103.34 Million | CN¥138.28 Million | — |